Previous Page
Picosun Oy, a leading atomic layer deposition (ALD) equipment manufacturer has co-organized the 1st International Conference on ALD Applications and 2nd China ALD Conference in cooperation with Fudan University, one of China’s top universities. The event took place in Shanghai at Fudan University’s premises. The conference attracted approximately 100 parti- cipants and high quality presentations and posters were presented by top ALD researchers around the world. The topics covered a wide range of applications, ALD fundamentals, as well as the most advanced research results in microelectronic devices, integration, and nanosciences.
"China is one of the fastest growing ALD communities with many top research institutes and industries working on exciting applications. Thanks to the organizing committee and excellent speakers, we have seen some of the world’s most advanced research being actively developed and discussed during this event. The already second China ALD conference has become a central event to broaden the cooperation between research groups in China and throughout the world," states Dr. Wei-Min Li, Applications Director of Picosun. Picosun Oy is also joining the China-Finland Nano Innovation Center, opened November 02, 2012. The center, located in the city of Suzhou, Jiangsu Province in the Eastern China, was initiated by Ministry of Science and Technology (MOST) of China and Ministry of Employment and the Economy (TEM) of Finland.
pSivida Corp. (NASDAQ: PSDV; ASX: PVA) announced financial results for its fourth quarter and fiscal year ended June 30, 2012. Revenues for the fiscal year ended June 30, 2012 totaled $3.5 million compared to $5.0 million for the prior fiscal year. Revenues in both years included royalty income from sales of Retisert® by Bausch & Lomb and revenue recognition from the June 2011 amendment and restatement of the Pfizer collaboration agreement. In addition, fiscal 2012 reflected revenue recognition from the July 2011 termination of the Intrinsiq license agreement. For the year ended June 30, 2012, pSivida reported a net loss of $24.8 million, or $1.19 per share, compared to a net loss of $8.6 million, or $0.44 per share, for the prior fiscal year. Fiscal year 2012 results included a $14.8 million impairment charge for pSivida’s finite-lived intangible assets arising from the November 2011 complete response letter for ILUVIEN for DME and the resulting significant decrease in pSivida’s share price. Revenues for the fiscal 2012 fourth quarter were $699,000 compared to $3.7 million for the fourth quarter a year earlier. The fiscal 2011 fourth quarter included $3.3 million of revenue recognition from the amended Pfizer collaboration agreement. pSivida reported a net loss of $2.3 million, or $0.11 per share, for the fourth quarter ended June 30, 2012, compared to a net loss of $140,000, or $0.01 per share, for the fourth quarter of the prior year.
At June 30, 2012, cash, cash equivalents and marketable securities totaled $14.6 million. In August 2012, the Company completed a registered direct offering of shares of common stock and warrants raising net proceeds of $4.7 million.